tbuckley/cabot-search huggingface dataset:
An important role of heparan sulfate proteoglycan (perlecan) in a model system for the deposition and persistence of fibrillar aβ-amyloid in rat brain
Authors: Alan D. Snow, Raymond Sekiguchi, David Nochlin, Paul Fraser, Koji Kimata, Akihiro Mizutani, Mikio Arai, Wayne A. Schreier, David G. Morgan
Journal: Neuron (1994)
ANGIOSCOPIC EVALUATION FOR NEIONTIMAL COVERAGE IS USEFUL TO ASSESS THE ARTERIAL REPAIR FOLLOWING DRUG–ELUTING STENT IMPLANTATION FOR NATIVE CORONARY ARTERY IN PATIENTS
Authors: Masaki Awata, Takayuki Ishihara, Masashi Fujita, Tetsuya Watanabe, Osamu iida, Shin Okamoto, Tomoharu Dohi, Kiyonori Nanto, Takashi Kanda, tatsuya shiraki, Takuma Iida, Shinsuke Nanto, Masaaki Uematsu
Journal: Journal of the American College of Cardiology (2013)
A study of peripheral leucocyte migration in agarose medium in inflammatory bowel disease
Authors: W. Bartnik, E. T. Swarbrick, C. Williams
Journal: Gut (1974)

THE MIGRATION OF PERIPHERAL LEUCOCYTES FROM PATIENTS WITH INFLAMMATORY BOWEL DISEASE WAS INVESTIGATED USING AN AGAROSE PLATE TECHNIQUE AND THREE ANTIGENIC MATERIALS: (1) the enterobacterial common antigen of Kunin; (2) extract from germ-free rat faeces; and (3) Kveim suspension from a sarcoid spleen K19. Inhibition of migration was obtained only with Kunin antigen. It was present in 11 out of 20 patients with ulcerative colitis and in four out of 20 patients with Crohn's disease but in only one out of 33 control subjects. These findings suggest the possibility that a state of cellular immunity to enterobacterial common antigen may exist in inflammatory bowel disease. Lack of cellular reactivity to extract from germ-free faeces and Kveim suspension is in contrast with the results obtained by others by means of the capillary tube method and requires further investigation.
Red cell distribution width as a marker of impaired exercise tolerance in patients with chronic heart failure
Authors: Emeline M. Van Craenenbroeck, Aline J. Pelle, Paul J. Beckers, Nadine M. Possemiers, Christian Ramakers, Christiaan J. Vrints, Viviane Van Hoof, Johan Denollet, Viviane M. Conraads
Journal: European Journal of Heart Failure (2011)
Pressure Ulcers: The Benefits and Costs of New Therapies
Authors: Gregg A. Pane
Journal: JAMA (1993)

<h3>To the Editor.</h3> —Ferrell et al<sup>1</sup>are to be congratulated for a well-designed study that has added to the body of literature concerning the treatment of pressure ulcers. In developing a clinical practice guideline on pressure ulcers in adults,<sup>2</sup>the Agency for Health Care Policy and Research reviewed 13 clinical studies examining the effects of pressure-reducing devices on the incidence of pressure ulcers, only three of which were randomized controlled trials. They concluded that although there is evidence pressure-reducing devices can decrease the incidence of pressure ulcers, there is no evidence to suggest that one type of device is more effective than another. One problem with the present study is that it compares newer, high-cost, low-air-loss bed technology with a basic foam mattress. Other available devices include gel-foam mattresses, full-gel mattresses, and alternating air support mattresses. There are also important roles for aggressive risk assessment, education, and skin
Papanicolaou Smear Screening and Cervical Cancer
Authors: Björn Stenkvist
Journal: JAMA (1984)

More than 90% of the total female population of three Swedish counties between the ages of 30 and 59 years, 53% of women between 60 and 69 years, and 25% of women older than 70 years were screened for cervical cancer with the Papanicolaou smear over a ten-year period. The uniqueness of the study is that in Sweden it is possible to follow up the entire population during their lifetimes via a population register, which has its roots in the 17th century, natural to Swedes but almost incomprehensible in the United States or United Kingdom. Every Papanicolaou smear taken was computer recorded and linked on an individual level to the cancer registry. There were 207,455 women followed up for ten years. No women were lost to follow-up. There was a 75% decrease in invasive cervical cancer incidence among women who had smears taken at least once during the ten-year period. Among those women who had never had smears taken, the incidence of invasive cervical cancer was four times as great as among those women who had been examined at least once. We estimate that the system proposed by Swedish Medical Board (at least one smear every three years) for cervical cancer screening can reduce the incidence of invasive cervical cancer to a level between one and five cases per 100,000 women per year in a completely screened population.
Arteriosclerotic Heart Disease in Roseto, Pennsylvania
Authors: Ancel Keys
Journal: JAMA (1966)

Data from a recent electrocardiographic survey provide no support for the claim that people in the town of Roseto, Pa, are relatively protected from myocardial infarction. The evidence offered from death data for 1955 to 1961 does not prove that in those years the people of Roseto differed significantly from average US white residents in the rate of death from arteriosclerotic heart disease. Consideration of the diet suggests that in the past Rosetans should have enjoyed considerable protection from arteriosclerotic heart disease. Failure to establish that fact could be expected from the inadequate size of the population concerned. There is no basis to propose a protective effect of the emotional climate of Roseto.
Non-ionic amphiphilic biodegradable PEG–PLGA–PEG copolymer enhances gene delivery efficiency in rat skeletal muscle
Authors: Chien-Wen Chang, Donghoon Choi, Won Jong Kim, James W. Yockman, Lane V. Christensen, Yong-Hee Kim, Sung Wan Kim
Journal: Journal of Controlled Release (2006)
SATB1 dictates expression of multiple genes including IL-5 involved in human T helper cell differentiation
Authors: Helena Ahlfors, Amita Limaye, Laura L. Elo, Soile Tuomela, Mithila Burute, Kamal Vishnu P. Gottimukkala, Dimple Notani, Omid Rasool, Sanjeev Galande, Riitta Lahesmaa
Journal: Blood (2010)
NEOPTERIN PREDICTS LEFT VENTRICULAR REMODELING IN PATIENTS WITH ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION UNDERGOING PRIMARY PERCUTANEOUS CORONARY INTERVENTION
Authors: Alberto Dominguez-Rodriguez, Pedro Abreu-Gonzalez, Sima Samimi-Fard, Eduardo Arroyo-Ucar, Ruben Juarez-Prera, Antonio Lara-Padrón, Francisco Bosa-Ojeda, Pablo Avanzas, Juan C. Kaski
Journal: Journal of the American College of Cardiology (2010)
Spurious thrombocytopenia produced by the interaction of rheumatoid factor with antiplatelet antibody
Authors: Thomas R. Poskitt, Paula K. F. Poskitt
Journal: American Journal of Hematology (1985)

Abstract A patient had spurious thrombocytopenia resulting from a mechanism not previously described. Whereas in prior reports the in vitro phenomenon of platelet clumping has been effected by either EDTA‐dependent or temperature‐dependent antibodies capable of direct platelet agglutination, neither the IgG nor the IgM fractions of this patient's serum demonstrated such activity. However, agglutination was produced by incubating allogeneic platelets with the IgG fraction followed by a room temperature incubation with the rheumatoid factor‐positive IgM fraction. The data support a new mechanism for spurious thrombocytopenia resulting from the interaction of a cold‐reactive rheumatoid factor with antiplatelet antibody.
LEFT-RIGHT SUBTRACTION IMAGES AS A DIAGNOSTIC AID IN 99mTc-HMPAO SPECT OF THE BRAIN
Authors: A. Lukban, C. Man, A. Olson, G. Schiller
Journal: Clinical Nuclear Medicine (1996)

RADIATION PHYSICS LAB, Box 1209, STATE UNIVERSITY OF NEW YORK/HEALTH SCIENCE CENTER AT BROOKLYN, 450 CLARKSON AVENUE, BROOKLYN, NY 11213.
Requirement of an integrated immune response for successful neuroattenuated HSV-1 therapy in an intracranial metastatic melanoma model
Authors: Cathie G Miller, Nigel W Fraser
Journal: Molecular Therapy (2003)

Neuroattenuated herpes simplex virus ICP34.5 mutants slow progression of preformed tumors and lead to complete regression of some tumors. Although this was previously thought to be due to viral lysis of infected tumor cells, it is now understood that there is an immune component to tumor destruction. We have previously shown that no difference in survival is seen in lymphocyte-depleted mice after viral or mock therapy of syngeneic intracranial melanomas. We have also demonstrated the presence of a wide spectrum of immune cells following viral therapy, including larger percentages of CD4+ T cells and macrophages. In this paper, the contribution of the immune system to tumor destruction has been further delineated. Viral therapy of intracranial melanoma induces a tumor-specific cytotoxic and proliferative T cell response. However, there is no increase following viral therapy in either serum tumor antibody levels or viral-neutralizing antibodies. Thus specific T cell responses appear to mediate viral-elicited prolongation in survival. These data suggest that designing new viruses capable of augmenting T cell responses may induce stronger tumor destruction upon viral therapy.
IMPACT OF ANGIOSOME IN ENDOVASCULAR THERAPY ON THE LIMB SALVAGE FOR THE PATIENTS WITH CRITICAL LIMB ISCHEMIA PRESENTING WITH ISOLATED INFRAPOPLITEAL LESIONS
Authors: Osamu Iida, Masaaki Uematsu, Yoshimitsu Soga, Kenji Suzuki, Hiroyoshi Yokoi, Masakiyo Nobuyoshi, Naoto Inoue, Shinsuke Nanto, Seiki Nagata
Journal: Journal of the American College of Cardiology (2011)
Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells
Authors: Nicola Gagliani, Chiara F Magnani, Samuel Huber, Monica E Gianolini, Mauro Pala, Paula Licona-Limon, Binggege Guo, De'Broski R Herbert, Alessandro Bulfone, Filippo Trentini, Clelia Di Serio, Rosa Bacchetta, Marco Andreani, Leonie Brockmann, Silvia Gregori, Richard A Flavell, Maria-Grazia Roncarolo
Journal: Nature Medicine (2013)
Impaired Glucose Transporter Activity in Pressure-Overload Hypertrophy Is an Early Indicator of Progression to Failure
Authors: I. Friehs, A. M. Moran, C. Stamm, S. D. Colan, K. Takeuchi, H. Cao-Danh, C. M. Rader, F. X. McGowan, P. J. del Nido
Journal: Circulation (1999)

Severe hypertrophy and heart failure are important risk factors in cardiac surgery. Early adaptive changes in hypertrophy include increased ventricular mass-to-cavity volume ratio (M/V ratio) and increased dependence on glucose for energy metabolism. However, glucose uptake is decreased in the late stages of hypertrophy when ventricular dilatation and failure are present. We hypothesized that impaired glucose uptake would be evident early in the progression of hypertrophy and associated with the onset of ventricular dilatation.Ten-day-old rabbits underwent banding of the descending aorta. Development of hypertrophy was followed by transthoracic echocardiography to measure left ventricular M/V ratio. Glucose uptake rate, as determined by (31)P-nuclear magnetic resonance spectroscopy measuring 2-deoxyglucose conversion to 2-deoxyglucose-6-phosphate, was measured in isolated perfused hearts obtained from banded rabbits when M/V ratio had increased by 15% from baseline (compensated hypertrophy) and by 30% from baseline (early-decompensated hypertrophy). In age-matched control animals, the rate of glucose uptake was 0.61+/-0.08 micromol x g of wet weight(-1) x 30 min(-1) (mean+/-SEM). With a 15% M/V ratio increase, glucose uptake rate remained at control levels (0.6+/-0.05 micromol x g of wet weight(-1) x 30 min(-1)), compared with hearts with 30% increased M/V ratios, where glucose uptake was significantly lower (0.42+/-0.05 micromol x g of wet weight(-1) x 30 min(-1); P</=0.05). Glucose transporter protein expression was the same in all groups.Glucose uptake rate is maintained during compensated hypertrophy. However, coinciding with severe hypertrophy, preceding ventricular dilatation, and glucose transporter protein downregulation, glucose uptake is significantly decreased. Because of the increased dependence of the hypertrophied hearts on glucose use, we speculate that this impairment may be a contributing factor in the progression to failure.
Liberating Data to Transform Health Care
Authors: Erika G. Martin, Natalie Helbig, Nirav R. Shah
Journal: JAMA (2014)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The coiled-coil domain and Tyr177 of bcr are required to induce a murine chronic myelogenous leukemia–like disease by bcr/abl
Authors: Yiping He, Jason A. Wertheim, Lanwei Xu, Juli P. Miller, Fredrick G. Karnell, John K. Choi, Ruibao Ren, Warren S. Pear
Journal: Blood (2002)
Lymphocyte Changes in Viral Infections
Authors: PETER D. UTSINGER
Journal: Annals of Internal Medicine (1975)

Letters1 July 1975Lymphocyte Changes in Viral InfectionsPETER D. UTSINGER, M.D.PETER D. UTSINGER, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-83-1-82_1 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptIt has long been noted that lymphopenia may develop during certain viral infections, and it has recently been noted that the ratio of lymphocyte subpopulations may change during viral infections (1-5). Both increases and decreases in the absolute number and percentage of "T" lymphocytes and "B" lymphocytes have been found. However, in most studies the diagnosis of the viral infection is clinical, the measurement of the lymphocyte subpopulations is not done at any consistent time in reference to the onset of the viral infection, and the percentage of monocytes has not been measured.Recently, we have had the opportunity to...References1. BENJAMINWARD BS: Leukocytic response to measels. Am J Dis Child 44:921, 963, 1932 Google Scholar2. HENLEHENLESTOKES WGJ: Demonstration of the efficacy of vaccination against influenza type A by experimental infection of human beings. J Immunol 46:163-175, 1943 Google Scholar3. MANGIDWYERNEIDERMAN RJJ: Decreased circulating T cells during viral pharyngitis. Ann Intern Med 81:557-558, 1974 LinkGoogle Scholar4. WYBRANFUDENBERG JH: Thymus-derived rosette-forming cells in various human disease states: cancer, lymphoma, bacterial and viral infections, and other diseases. J Clin Invest 52:1026-1032, 1973 CrossrefMedlineGoogle Scholar5. THORLEYSMITHSANFORD JJJ: B and T lymphocytes during systemic infections in humans (abstract). Clin Res 22:445, 1974 Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: PETER D. UTSINGER, M.D.Affiliations: Division of Rheumatology and Clinical Immunology Department of Medicine The School of Medicine The University of North Carolina Chapel Hill, North Carolina 27514 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byCellular immunity abnormalities in patients with recurrent Bell's palsyPeripheral Blood T and B Lymphocyte Subpopulations in Bell's PalsyBlood and the Hematopoietic SystemImmunity in wart resolutionHematologySEVERE DISSEMINATED ADENOVIRUS INFECTION SUCCESSFULLY TREATED WITH A THYMIC HUMORAL FACTOR, THFInfluenza: Response of T-Cell Lymphopenia to Thymosin 1 July 1975Volume 83, Issue 1Page: 82-82KeywordsLymphocytesLymphopeniaMonocytes ePublished: 1 December 2008 Issue Published: 1 July 1975 PDF downloadLoading ...
Oligospermic infertility associated with an androgen receptor mutation that disrupts interdomain and coactivator (TIF2) interactions
Authors: Farid J. Ghadessy, Joyce Lim, Abdullah A.R. Abdullah, Valerie Panet-Raymond, Chee Keong Choo, Rose Lumbroso, Thein G. Tut, Bruce Gottlieb, Leonard Pinsky, Mark A. Trifiro, Eu Leong Yong
Journal: Journal of Clinical Investigation (1999)

Structural changes in the androgen receptor (AR) are one of the causes of defective spermatogenesis. We screened the AR gene of 173 infertile men with impaired spermatogenesis and identified 3 of them, unrelated, who each had a single adenine→guanine transition that changed codon 886 in exon 8 from methionine to valine. This mutation was significantly associated with the severely oligospermic phenotype and was not detected in 400 control AR alleles. Despite the location of this substitution in the ligand-binding domain (LBD) of the AR, neither the genital skin fibroblasts of the subjects nor transfected cell types expressing the mutant receptor had any androgen-binding abnormality. However, the mutant receptor had a consistently (approximately 50%) reduced capacity to transactivate each of 2 different androgen-inducible reporter genes in 3 different cell lines. Deficient transactivation correlated with reduced binding of mutant AR complexes to androgen response elements. Coexpression of AR domain fragments in mammalian and yeast two-hybrid studies suggests that the mutation disrupts interactions of the LBD with another LBD, with the NH2-terminal transactivation domain, and with the transcriptional intermediary factor TIF2. These data suggest that a functional element centered around M886 has a role, not for ligand binding, but for interdomain and coactivator interactions culminating in the formation of a normal transcription complex.
INTERACTION OF ETHNICITY WITH HIGH-DENSITY LIPOPROTEIN-CHOLESTEROL PREDICTS ADVERSE CLINICAL OUTCOME OF ASIAN SUBPOPULATIONS WITH ACUTE CORONARY SYNDROME
Authors: Angela Koh, Julian Tan, Kenneth Guo, Stanley Chia, Terrance Chua, Tian Hai Koh, Jack Tan
Journal: Journal of the American College of Cardiology (2012)
Increasing Tumor Antigen Expression Overcomes “Ignorance” to Solid Tumors via Crosspresentation by Bone Marrow-Derived Stromal Cells
Authors: Michael T. Spiotto, Ping Yu, Donald A. Rowley, Michael I. Nishimura, Stephen C. Meredith, Thomas F. Gajewski, Yang-Xin Fu, Hans Schreiber
Journal: Immunity (2002)
Abstract 4657: Evaluation of genomic profiling in the GALAXY-1 (NCT01348126), a randomized Phase 2b study of ganetespib in combination with docetaxel versus docetaxel alone as second line therapy in patients with advanced NSCLC
Authors: Dean Fennell, Alexey Antonov, Miguel L. Martins, Sanjay Popat, Suresh S. Ramalingam, James Spicer, Vojislav M. Vukovic, Iman El-Hariry, Vienna Reichert, Rafael Rosell
Journal: Cancer Research (2014)

Abstract Background: Inhibition of Hsp90, a key molecular chaperone required for activation of many oncoproteins, can lead to cancer cell death. Ganetespib (G) is a 2nd generation Hsp90 inhibitor (Hsp90i) that has single agent clinical activity in patients with ALK, KRAS, HER2, and BRAF mutations. G also inhibits pathways implicated in resistance to taxanes, including hypoxia pathways (HIF-1α) as well as cell-cycle and DNA repair pathways. Combination of G with docetaxel (D) has shown synergy in NSCLC xenografts and prolongation of progression-free survival (PFS) and overall survival (OS) of patients with NSCLC adenocarcinoma in interim analyses of the GALAXY-1 trial. Methods: Patients enrolled in GALAXY-1 (n=253) receive D 75 mg/m2 on D1 of a 3-week treatment cycle; combination arm patients receive G 150 mg/m2 on D1 and D15 in addition. The co-primary endpoints are PFS in patients with elevated baseline level of serum LDH and PFS in the mutant KRAS population. PFS and OS in all adenocarcinoma patients are key secondary endpoints. Genomic profiling using Affymetrix Oncoscan™ was performed on archival tissues obtained at baseline, with the goal of determining biomarkers predictive of ganetespib activity Results: Tumor tissue samples from 65 patients and 26 matched normal tissues were processed on the Affymetrix OncoScan™ FFPE Express 2.0 Services assay. The OncoScan™ FFPE Express 2.0 assay contains 332941 copy number probes. After removing samples with average call rates lower than 90%, 296522 markers on chromosome 1-22 were selected for copy number analyses. For preliminary evaluation of interactions between copy number aberrations and treatment response in the G arm, a genome scale Kaplan-Meier Estimates PFS analysis at each of 296522 markers was performed. Conclusions: Genomic profiling using OncoScan™ is utilized in the GALAXY-1 trial to identify biomarkers of response/resistance to ganetespib administered in combination with docetaxel. Complete analyses will be presented at the meeting. Note: This abstract was not presented at the meeting. Citation Format: Dean Fennell, Alexey Antonov, Miguel L. Martins, Sanjay Popat, Suresh S. Ramalingam, James Spicer, Vojislav M. Vukovic, Iman El-Hariry, Vienna Reichert, Rafael Rosell. Evaluation of genomic profiling in the GALAXY-1 (NCT01348126), a randomized Phase 2b study of ganetespib in combination with docetaxel versus docetaxel alone as second line therapy in patients with advanced NSCLC. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 4657. doi:10.1158/1538-7445.AM2014-4657
ACC/AHA Guidelines for Coronary Angiography: Executive Summary and Recommendations
Authors: Patrick J. Scanlon, David P. Faxon, Anne-Marie Audet, Blase Carabello, Gregory J. Dehmer, Kim A. Eagle, Ronald D. Legako, Donald F. Leon, John A. Murray, Steven E. Nissen, Carl J. Pepine, Rita M. Watson, James L. Ritchie, Raymond J. Gibbons, Melvin D. Cheitlin, Kim A. Eagle, Timothy J. Gardner, Arthur Garson, Richard O. Russell, Thomas J. Ryan, Sidney C. Smith
Journal: Circulation (1999)
UNUSUAL BONE CHANGES CAUSED BY A SMALL PRIMARY BRONCHIOGENIC CARCINOMA
Authors: HENRY B. THOMAS
Journal: JAMA (1928)

Among the disorders of bones difficult to diagnose clinically are those caused by metastases from a relatively small carcinoma of some parenchymatous tissue, such as the prostate or the lungs. Others<sup>1</sup>have commented on this, and with practically all the patients the primary carcinoma itself has been a silent focus so far as arousing clinical symptoms is concerned. The symptoms associated with the bone changes are especially impressive to the attending physician, because, in his efforts to determine the disorder present, advice is sought from others, and every examination is made which might possibly be helpful in reaching a correct diagnosis. The purpose of the present report is to place on record an account of unusual changes of the bones